Five Prime Therapeutics Inc (FPRX) Expected to Post Quarterly Sales of $6.25 Million

Equities analysts forecast that Five Prime Therapeutics Inc (NASDAQ:FPRX) will announce sales of $6.25 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Five Prime Therapeutics’ earnings, with estimates ranging from $5.00 million to $7.50 million. Five Prime Therapeutics posted sales of $7.82 million during the same quarter last year, which would suggest a negative year over year growth rate of 20.1%. The firm is scheduled to announce its next quarterly earnings report on Tuesday, August 14th.

On average, analysts expect that Five Prime Therapeutics will report full-year sales of $48.25 million for the current fiscal year, with estimates ranging from $32.50 million to $60.00 million. For the next financial year, analysts anticipate that the business will report sales of $34.25 million per share, with estimates ranging from $20.00 million to $60.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for Five Prime Therapeutics.

Five Prime Therapeutics (NASDAQ:FPRX) last announced its quarterly earnings data on Tuesday, May 8th. The biotechnology company reported ($0.63) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.55) by ($0.08). The company had revenue of $32.49 million for the quarter, compared to analysts’ expectations of $37.50 million. Five Prime Therapeutics had a negative net margin of 221.74% and a negative return on equity of 44.36%.



A number of analysts have commented on FPRX shares. BMO Capital Markets reduced their target price on Five Prime Therapeutics from $75.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 28th. Nomura reduced their target price on Five Prime Therapeutics from $94.00 to $25.00 and set a “buy” rating for the company in a report on Wednesday, February 28th. Zacks Investment Research lowered Five Prime Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 2nd. ValuEngine raised Five Prime Therapeutics from a “strong sell” rating to a “sell” rating in a report on Monday, April 2nd. Finally, BidaskClub lowered Five Prime Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, March 17th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus target price of $33.00.

Institutional investors have recently bought and sold shares of the business. Millennium Management LLC grew its holdings in shares of Five Prime Therapeutics by 35.7% in the first quarter. Millennium Management LLC now owns 357,747 shares of the biotechnology company’s stock worth $6,146,000 after acquiring an additional 94,035 shares during the period. Hilltop Holdings Inc. bought a new stake in shares of Five Prime Therapeutics in the first quarter worth $893,000. California State Teachers Retirement System grew its holdings in shares of Five Prime Therapeutics by 16.9% in the first quarter. California State Teachers Retirement System now owns 50,093 shares of the biotechnology company’s stock worth $861,000 after acquiring an additional 7,238 shares during the period. Barclays PLC grew its holdings in shares of Five Prime Therapeutics by 261.8% in the first quarter. Barclays PLC now owns 25,447 shares of the biotechnology company’s stock worth $437,000 after acquiring an additional 18,414 shares during the period. Finally, The Manufacturers Life Insurance Company grew its holdings in shares of Five Prime Therapeutics by 17.8% in the first quarter. The Manufacturers Life Insurance Company now owns 25,032 shares of the biotechnology company’s stock worth $430,000 after acquiring an additional 3,782 shares during the period. 90.98% of the stock is owned by institutional investors and hedge funds.

Shares of Five Prime Therapeutics opened at $17.13 on Friday, MarketBeat.com reports. The firm has a market cap of $609.47 million, a price-to-earnings ratio of -3.18 and a beta of 3.41. Five Prime Therapeutics has a 12-month low of $15.66 and a 12-month high of $48.87.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of immuno-oncology protein therapeutics. The company's product candidates include Cabiralizumab, an antibody that inhibits colony stimulating factor-1 receptor that is in Phase Ia/Ib clinical trials for the treatment of various cancers in combination with nivolumab; and is in Phase I/II clinical trials for the treatment of pigmented villonodular synovitis tumor.

Get a free copy of the Zacks research report on Five Prime Therapeutics (FPRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply